Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

You will be redirected in 10 seconds.